Fulcrum Therapeutics Appoints Katina Dorton to its Board of Directors

NEXT STORY
Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020
PREV STORY
Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Fulcrum Therapeutics Appoints Katina Dorton to its Board of Directors

NEXT STORY
Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020
PREV STORY
Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Predictive Oncology Inc.’s Wholly Owned Subsidiary, TumorGenesis, Partners with Cellevate AB

author_avatar
NASDAQ Market News

eFFECTOR Appoints Barbara Klencke, M.D., to Board of Directors

author_avatar
NASDAQ Market News

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

author_avatar
NASDAQ Market News